Skip to content

Study on the Efficacy of Shexiang Baoxin Pill in the Treatment of Coronary Microvascular Disease Based on TCM Syndrome Types

Study on the Efficacy of Shexiang Baoxin Pill in the Treatment of Coronary Microvascular Disease Based on TCM Syndrome Types

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000379
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-01-22
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Microvascular Disease

Interventions

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
28 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Gender unrestricted, aged 18-85 years 2.Meeting the diagnostic criteria for coronary microvascular disease (IMR = 30) 3.Presenting with clinical symptoms (such as chest tightness, suffocation, pain, or palpitations-one or more of these symptoms) 4.Subjects are informed and voluntarily sign the informed consent form

Exclusion criteria

Exclusion criteria: 1.Acute myocardial infarction within the past 3 months 2.History of acute heart failure episode within the past 3 months 3.Ejection fraction < 40% 4.History of lower extremity arterial stent implantation 5.Complicated by severe valvular stenosis or regurgitation 6.Use of traditional Chinese patent medicines such as Compound Danshen Dripping Pills within the past 3 months 7.Complicated by hyperthyroidism 8.Complicated by lower extremity venous thrombosis 9.Presence of cognitive impairment or inability to cooperate with the investgator 10.Complicated by moderate to severe pulmonary hypertension 11.Complicated by hemorrhagic diseases, currently taking oral anticoagulants, or requiring anticoagulant therapy for existing conditions 12.Newly developed lower extremity venous thrombosis within the past month. 13.Exclusion of individuals who are pregnant, breastfeeding, or have an allergic constitution or other similar conditions.

Design outcomes

Primary

MeasureTime frame
Seattle Angina Scale score;

Secondary

MeasureTime frame
Improvement rate of characteristic parameters of magnetocardiography;Left Ventricular Ejection Fraction;Early to Late Diastolic Mitral Inflow Velocity Ratio; Stroke Volume;Systemic Vascular Resistance;Cardiac Output;

Countries

China

Contacts

Public ContactXingxue Pang

Dongzhimen Hospital, Beijing University of Chinese Medicine

20240931524@bucm.edu.cn151 1024 7839

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026